Semax is a synthetic heptapeptide analog of ACTH(4-10) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It has been approved in Russia and several CIS countries as a neuroprotective and nootropic agent since 1994. Research demonstrates that Semax enhances neurotrophic factor expression, modulates neurotransmitter systems, and provides neuroprotection through antioxidant and anti-inflammatory mechanisms. Its intranasal delivery bypasses the blood-brain barrier, providing direct CNS access.
Development and Structure
Semax was developed in the 1980s by a team led by Nikolai Myasoedov at the Institute of Molecular Genetics, Russian Academy of Sciences. The peptide is based on the ACTH(4-10) fragment (Met-Glu-His-Phe-Pro-Gly-Pro), which was known to have neurotrophic activity independent of ACTH’s adrenocortical effects. The C-terminal Pro-Gly-Pro tripeptide was added to enhance metabolic stability and extend the peptide’s biological half-life from minutes to several hours.
Unlike full-length ACTH, Semax does not stimulate adrenal cortisol production or affect the hypothalamic-pituitary-adrenal (HPA) axis, making it a purely neurotropic compound. The separation of neurotrophic from endocrine activity was a key design goal. Semax’s molecular weight is 813 Da, small enough for efficient intranasal absorption and blood-brain barrier penetration.
Neurotrophic Factor Modulation
The most well-characterized mechanism of Semax is upregulation of neurotrophic factors. In rodent models and cell culture studies, Semax significantly increases expression of brain-derived neurotrophic factor (BDNF) and its receptor TrkB, nerve growth factor (NGF), and glial cell line-derived neurotrophic factor (GDNF). These neurotrophins are critical for neuronal survival, synaptic plasticity, and cognitive function.
BDNF upregulation by Semax occurs through activation of the CREB (cAMP response element-binding protein) transcription factor pathway. CREB phosphorylation at Ser133 increases BDNF gene transcription, producing sustained elevation of BDNF protein levels in hippocampal and cortical neurons. This mechanism is particularly relevant because BDNF decline is associated with cognitive impairment, depression, and neurodegenerative disease.
Semax also modulates the expression of hundreds of genes in the brain. Transcriptomic studies using microarray analysis revealed that Semax treatment alters expression of genes involved in neurotransmitter signaling, immune regulation, vascular function, and neuroprotection. The scope of gene expression changes suggests broad neuroprotective and neuroplasticity-promoting effects.
Neurotransmitter Effects
Semax modulates multiple neurotransmitter systems. It enhances serotonergic transmission by increasing serotonin turnover and 5-HT1A receptor sensitivity. Dopaminergic modulation involves enhanced dopamine synthesis and D2 receptor expression in the striatum. Cholinergic effects include increased acetylcholine release and muscarinic receptor responsiveness in hippocampal circuits—directly relevant to memory formation and cognitive performance.
Neuroprotection: Stroke Research
Semax’s clinical approval in Russia is primarily for ischemic stroke. In controlled clinical studies, intranasal Semax administration within the first 6-12 hours of ischemic stroke improved neurological outcome scores, reduced infarct volume on follow-up imaging, and accelerated functional recovery compared to standard care alone. The neuroprotective mechanisms involve reduction of glutamate-mediated excitotoxicity, mitigation of oxidative stress through upregulation of antioxidant enzymes (SOD, catalase, glutathione peroxidase), and suppression of post-ischemic neuroinflammation.
In the penumbra (the ischemic border zone where neurons are stressed but not yet dead), Semax promotes survival by maintaining mitochondrial membrane potential, reducing caspase-3 activation, and supporting energy metabolism. These effects provide a time-dependent window of neuroprotection that complements reperfusion therapy.
Cognitive Enhancement Research
In healthy animal models, Semax improves performance on learning and memory tasks including Morris water maze, passive avoidance, and object recognition. These effects are attributed to enhanced hippocampal long-term potentiation (LTP)—the synaptic mechanism underlying memory formation—driven by BDNF and cholinergic upregulation.
Human clinical data from Russian studies suggest improvements in attention, working memory, and cognitive processing speed in both healthy subjects and those with mild cognitive impairment. However, these studies have not been replicated in Western clinical trial settings, and methodological details are sometimes difficult to fully evaluate from translated publications.
Variants: N-Acetyl Semax and Semax Amidate
Modified forms of Semax have been developed for enhanced potency and stability. N-Acetyl Semax (NA-Semax) features an acetyl group on the N-terminal methionine, improving blood-brain barrier penetration and extending the peptide’s half-life. N-Acetyl Semax Amidate (NASA) adds both acetylation and C-terminal amidation for maximal stability and bioavailability. These variants are primarily available as research tools and have not undergone independent clinical evaluation.
Frequently Asked Questions
What is Semax?
Semax is a synthetic heptapeptide derived from ACTH(4-10), approved in Russia for neurological conditions including stroke recovery and cognitive enhancement. It enhances neurotrophic factors and modulates neurotransmitter systems.
How does Semax work in the brain?
Semax increases BDNF and NGF expression, modulates serotonergic and dopaminergic neurotransmission, enhances cholinergic signaling, and provides antioxidant and anti-inflammatory neuroprotection.
What conditions has Semax been studied for?
Ischemic stroke recovery, traumatic brain injury, cognitive impairment, optic nerve atrophy, ADHD, and general nootropic enhancement. Russian clinical data supports stroke and cognitive applications.